Patient-Provider Communications About Pharmacogenomic Results Increase Patient Recall of Medication Changes
| Autor: | Kristen Lipstreuer, Mark J. Ratain, Tamar S. Polonsky, William Harper, Sang Mee Lee, Mark Siegler, Paige Galecki, Brittany A. Borden, Jay L. Koyner, David T. Rubin, Rita Nanda, David O. Meltzer, Robert T. Kavitt, Walter M. Stadler, Deborah L. Burnet, Yasmin Sacro, Andrew M. Davis, Matthew J. Sorrentino, Keith Danahey, Linda Patrick-Miller, Peter H. O'Donnell |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Prescription Drugs Point-of-Care Systems Pharmacogenomic Testing 030226 pharmacology & pharmacy Drug Prescriptions Article 03 medical and health sciences 0302 clinical medicine Genetics Medicine Humans Drug Recalls Disease management (health) Precision Medicine Pharmacology Physician-Patient Relations Recall business.industry Communication Research Disease Management Middle Aged Patient recall 030104 developmental biology Pharmacogenetics Family medicine Pharmacogenomics Molecular Medicine Genomic information Female Delivery system business Personal genomics |
| Zdroj: | The pharmacogenomics journal |
| ISSN: | 1473-1150 1470-269X |
| Popis: | Effective doctor–patient communication is critical for disease management, especially when considering genetic information. We studied patient-provider communications after implementing a point-of-care pharmacogenomic results delivery system to understand whether pharmacogenomic results are discussed and whether medication recall is impacted. Outpatients undergoing preemptive pharmacogenomic testing (cases), non-genotyped controls, and study providers were surveyed from October 2012–May 2017. Patient responses were compared between visits where pharmacogenomic results guided prescribing versus visits where pharmacogenomics did not guide prescribing. Provider knowledge of pharmacogenomics, before and during study participation, was also analyzed. Both providers and case patients frequently reported discussions of genetic results after visits where pharmacogenomic information guided prescribing. Importantly, medication changes from visits where pharmacogenomics influenced prescribing were more often recalled than non-pharmacogenomic guided medication changes (OR = 3.3 [1.6–6.7], p = 0.001). Case patients who had separate visits where pharmacogenomics did and did not, respectively, influence prescribing more often remembered medication changes from visits where genomic-based guidance was used (OR = 3.4 [1.2–9.3], p = 0.02). Providers also displayed dramatic increases in personal genomic understanding through program participation (94% felt at least somewhat informed about pharmacogenomics post-participation, compared to 61% at baseline, p = 0.04). Using genomic information during prescribing increases patient-provider communications, patient medication recall, and provider understanding of genomics, important ancillary benefits to clinical use of pharmacogenomics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink